BOARD OF DIRECTORS
Aiphi Nguyen
PharmD, CEO
View Profile
Dr. Aiphi Nguyen, is co-founder and the CEO: Aiphi has more than 18 years experience in the pharmaceutical industry and the investment bank with a strong entrepreneurship orientation in goals and choice. Aiphi held various positions with Bristol Myers Squib (BMS) in regulatory, medico-marketing within the peadiatric field for which she gained tractions such as world successful launch of a specific range products intented to the treatment of inborn metabolic disorders, notified in the BMS 2003 annual report.
Then, Aiphi steered her carrier into the investment bank working with valuation team supporting various life sciences mandates. Aiphi has a twofold background in pharmacy and business, is a PharmD and hold an MBA from Sorbone University, a master in corporate finance from ESCP Europe and “Challenge plus” startup certification from HEC.
Neuville Pascal
PhD
View Profile
Pascal Neuville, Ph.D.,Founder & former CEO of Domain Therapeutics is an accomplished figure in the biotech sector, known for co-founding and leading Domain Therapeutics as its CEO. His vision was pivotal in establishing the company as a leader in G-protein-coupled receptor (GPCR) drug development, with a strong emphasis on immuno-oncology. Throughout his career, Neuville fostered strategic partnerships and secured investments that accelerated the company’s growth and therapeutic innovation. His background also includes significant roles at Transgene and Faust Pharmaceuticals, where he gained deep expertise in drug discovery and development. Neuville continues to actively contribute to the biotech landscape.
Florence Lhospice
PharmD, PhD
View Profile
Florence Lhospice, PharmD, is widely regarded as an expert in antibody-drug conjugates (ADCs), with extensive experience from her leadership roles at both Innate Pharma and Emergence Therapeutics. At Innate Pharma, she advanced site-specific conjugation technologies, improving the homogeneity and therapeutic index of ADCs, which played a key role in their oncology pipeline. As Chief Development Officer at Emergence Therapeutics, she continued to push forward innovative ADC technologies. The acquisition of Emergence by Eli Lilly underscores the high value of her work and the strategic importance of the ADC innovations she helped to develop
Champavere Xavier
View Profile
CEO of Exicomes and Thinkeen, Former Cellectis subsidary’s CEO
Xavier Champavere is an experienced biotech leader with over 30 years in the industry, holding key roles at companies like Aventis Pasteur and Cellectis Bioresearch. He co-founded Thinkeen Global, a consultancy focused on commercial success in scientific sectors, and also serves as a Non-Executive Director at Moleac. His background includes international commercial management across Asia, Europe, and the Americas, with advanced training from INSEAD
Marc Vincenti
PharmD, MBA
View Profile
Global Director, Pierre Fabre
Marc Vincenti is a seasoned biotech executive with a broad range of leadership experience at Pierre Fabre, where he currently serves as Global Optimization Director for the International Business Unit. Throughout his career, Vincenti has held key roles, including General Manager and VP of Corporate Licensing & Acquisition, where he led strategic partnerships and business development efforts. He also advises on strategic initiatives at CERES BRAIN Therapeutics.